In yet another classic example, trastuzumab (HER2-targeting antibody) dramatically lessens the chances of breast cancer recurrence by targeting HER2, an important regulator of breast CSC self-renewal [140]. This evidence concerns the gene ERBB2 and breast carcinoma.